[Show abstract][Hide abstract] ABSTRACT: The choice of vascular access type is an important aspect of care for incident hemodialysis patients. However, data from the Centers for Medicare & Medicaid Services (CMS) Medical Evidence Report (form CMS-2728) identifying the first access for incident patients have not previously been validated. Medicare began requiring that vascular access type be reported on claims in July 2010. We aimed to determine the agreement between the reported vascular access at initiation from form CMS-2728 and from Medicare claims.
This retrospective study used a cohort of 9777 patients who initiated dialysis in the latter half of 2010 and were eligible for Medicare at the start of renal replacement therapy to compare the vascular access type reported on form CMS-2728 with the type reported on Medicare outpatient dialysis claims for the same patients. For each patient, the reported access from each data source was compiled; the percent agreement represented the percent of patients for whom the access was the same. Multivariate logistic analysis was performed to identify characteristics associated with the agreement of reported access.
The two data sources agreed for 94% of patients, with a Kappa statistic of 0.83, indicating an excellent level of agreement. Further, we found no evidence to suggest that agreement was associated with the patient characteristics of age, sex, race, or primary cause of renal failure.
These results suggest that vascular access data as reported on form CMS-2728 are valid and reliable for use in research studies.
[Show abstract][Hide abstract] ABSTRACT: Abstract
Introduction and Aims: With the advancement of immunosuppressive therapies, kidney survival in renal transplant patients improves over years. More patients with functioning graft were subject to infective and cardiovascular complications as well as malignancy. The present study aims at describing the epidemiology and risk factors of death with a functioning graft (DWFG) in renal transplant patients from registry data in Hong Kong
Methods: Registry data related to renal transplantation N = 3770) performing between April 1995 and April 2011 was retrieved from the Renal Registry / Organ Transplant System (RR/ OTS) of the Hong Kong Hospital Authority. DWFG is defined as death without need of returning to renal replacement therapy. Sex, age, modality (peritoneal dialysis, hemodialysis or none) and duration of renal replacement therapy before transplantation, cadaveric or living donor, history of renal transplant, graft failure date and its reason, date and cause of death, etiology of primary renal disease, co-morbidities including hypertension, diabetes, history of stroke, chronic lung disease, hepatitis B and C status and immunosuppressive therapies were included for analysis. Cox proportional hazard model was used for calculating hazard ratio of DWFG. Time series model were used for calculating patient-year at risk.
Results: There were 3770 renal transplant patients recorded in the Hong Kong Renal registry during the period of study. The mean age was 44.4 ± 11.9 years and 58.4% was male. Diabetes and hepatitis B corresponded to 21.1% and 10% of the patients respectively. Among the 603 deaths, 446 patients (74%) died with a functional graft. The DWFG accounts for 3.58, 1.93 and 1.78 death per 100 patient-years at risk in 1, 5 and 10 year after transplantation, respectively. Infection, cardiovascular disease, malignancy and liver failure accounted for 29.15%, 21.52%, 16.59% and 6.68% of patient died with a functioning graft. Using age < 35 yr as reference, HR of age of 30 to < 45 yr = 1.92 (95%C.I. = 1.285-2.87; p = 0.0015), HR of age 45 to < 55 yr = 2.908 (95%C.I. = 1.971-4.29; p = < 0.0001), HR of ageof 55 to < 65 yr = 6.032 (95%C.I. = 4.068-8.945; p < 0.0001) and HR of age ≥ 65 = 10.373 (95%C.I. = 6.729-15.991; p < 0.001). Male (HR = 1.378; 95% C.I. = 1.131-1.678; p = 0.0014), duration of renal replacement therapy before transplant (HR = 1.056; 95% C.I. = 1.029-1.094; p = 0.0006), transplant before 2003 (HR = 1.491; 95% C.I. = 1.203-1.847; p = 0.0003), hepatitis B status (HR = 1.562; 95%C.I. = 1.176-1.981; p = 0.0008) and deceased donor (HR=1.565; 95% C.I. = 1.010-2.522; p = 0.0454) was found to be independent risk factors. Hepatitis B patients had higher risk of death from liver failure (RR=14.25; p < 0.0001). 45% of liver failure occurred within first year of transplant but it continued to occur till the end of study whereas majority of malignancy occurs 3 to 10 years after transplant.
Conclusions: DWFG is common in deceased renal transplant patients in Hong Kong. Independent risk factors for DWFG include age, male, hepatitis B, deceased donor, duration of RRT before transplant and transplant before 2003. Hepatitis B is a potential modifiable risk factor and proper management before and after renal transplant should be considered in area where hepatitis B is endemic.
[Show abstract][Hide abstract] ABSTRACT: Hemoglobin level variability in hemodialysis patients is common, and has been associated with comorbidity, intercurrent illness, and mortality risk. We aimed to describe the influence of anemia management interventions (erythropoiesis-stimulating agents [ESAs], intravenous iron, and transfusions) on hemoglobin variability.
We studied all Medicare primary payer hemodialysis patients who survived and had ESA claims in the first 6 months of 2004 (n = 159,720). Monthly hemoglobin values were categorized as low (<11 g/dl), intermediate (11-12.5 g/dl), and high (>12.5 g/dl). Variability groups were classified based on lowest and highest hemoglobin categories during a 6-month observation period. ESA, intravenous iron, and transfusion use were characterized by variability group.
Patients with consistently low or low and intermediate hemoglobin received the highest ESA doses and the most frequent transfusions, while patients with consistently or intermittently intermediate or high hemoglobin received lower ESA doses and fewer transfusions. Intravenous iron doses were highest initially for patients with consistently high hemoglobin; these doses subsequently declined. Iron doses were lowest for patients with consistently intermediate hemoglobin.
Anemia management protocols describing coordinated administration of ESAs and iron may help to increase the number of patients achieving target hemoglobin levels.
American Journal of Nephrology 09/2009; 30(6):491-8. · 2.62 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: Awareness of hemoglobin level variability in dialysis patients is increasing, as is interest in its potential implications. In this retrospective, national study of associations between the degree of hemoglobin level variability in the first 6 mo of 2004 and subsequent mortality rates in the following 6 mo, 159,720 hemodialysis patients receiving epoetin therapy were studied. DESIGN, SETTING, PARTICIPANTS, MEASUREMENTS: Monthly hemoglobin values were categorized as low (L; < 11 g/dl), intermediate (I; 11 to 12.5 g/dl), and high (H; >12.5 g/dl). Variability groups were classified on the basis of the lowest and highest hemoglobin categories seen during the 6-mo observation period: low-low (L-L), 1.4%; intermediate-intermediate (I-I), 6.0%; high-high (H-H), 2.3%; low-intermediate (L-I), 18.3%; intermediate-high (I-H), 31.7%, and low-high (L-H), 40.2%.
On multivariate analysis, adjusted hazards ratios for subsequent mortality events were as follows: I-I, 1.0 (reference category); I-H, 1.02 (95% confidence interval [CI] 0.95 to 1.11); H-H, 1.06 (95% CI 0.93 to 1.21); L-H, 1.19 (95% CI 1.10 to 1.28); L-I, 1.44 (95% CI 1.33 to 1.56), and L-L, 2.18 (95% CI 1.93 to 2.45). Persistently and transiently low hemoglobin levels and highly variable hemoglobin levels were associated with increased risk of death; transiently and persistently high hemoglobin levels were not associated with increased risk of death. Bayesian modeling indicated that > or =3 mo with hemoglobin levels <11 g/dl may be associated with of increased risk of death.
Number of months with hemoglobin values below the target range, rather than hemoglobin variability itself, may be the primary driver of increased risk of death. Further research is needed to distinguish cause from effect and to understand the underlying mechanisms.
Clinical Journal of the American Society of Nephrology 02/2008; 3(1):133-8. · 5.07 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: Chronic kidney disease (CKD) is an important public health challenge due to increased risk of cardiovascular events and progression to end stage renal disease (ESRD). Because state Medicaid agencies cover some of their health care costs, they may have a particular interest in Medicare/Medicaid dually-enrolled patients. In this population we analyzed the interacting prevalence and costs for persons diagnosed with CKD, diabetes mellitus (DM), congestive heart failure (CHF), and ESRD. Diagnosis of CKD, DM, and CHF was defined by Medicare claims (Two Part B or one Part A claim with codes for the disease). Costs are total 2004 Medicare costs. Nationally, the 5.9% of patients diagnosed with CKD accounted for 16.6% of costs: a multiplier of 2.8. For DM the multiplier was 1.5 (28.4% of population; 42.4% of costs); for CHF the multiplier was 2.5 (13.8%; 34.2%). For ESRD the multiplier was 5.5 (1.9%; 10.2%). Among those diagnosed with CKD, 56% were also diagnosed with diabetes and 44% were also diagnosed with CHF. The 1.7% of the population with diagnoses of CKD, DM, and CHF accounted for 6.9% of costs: a multiplier of 4.1. State-level analyses were also performed. Size and costs of diagnosed populations varied widely while cost multipliers varied little. Sensitivity of claims-based CKD diagnosis is low, but specificity is high. So true prevalence is even higher than reflected in these analyses. CKD's high cost multiplier, broad overlap with DM and CHF, and relatively high prevalence has implications for disease management and prevention efforts.
135st APHA Annual Meeting and Exposition 2007; 11/2007
[Show abstract][Hide abstract] ABSTRACT: This study investigates provider practices regarding recombinant human erythropoietin (rHuEPO) dose when patient hemoglobin levels exceeded National Kidney Foundation-Dialysis Outcomes Quality Initiative target levels and reached 13 g/dL or greater (>or=130 g/L).
The study population (N = 167,796) was hemodialysis patients prevalent on January 1, 2003, who were on renal replacement therapy at least 90 days with Medicare as primary payer and rHuEPO claims in 2 or more consecutive months. Patient characteristics were obtained from the Centers for Medicare & Medicaid Services (CMS) Medical Evidence Report, and comorbid conditions were determined from Medicare claims. Providers and rHuEPO claims were linked by using CMS-assigned provider numbers and the CMS Annual End-Stage Renal Disease Facility Survey. Between-provider differences in patient characteristics were examined by using chi-square test, and provider effect on appropriate response, by using logistic regression.
DaVita's percentage of monthly claims for patients with hemoglobin levels of 13 g/dL or greater (>or=130 g/L; 16.7%) and mean monthly rHuEPO dose (54,299 units) were highest. Dialysis Clinic Inc's percentage of such claims (2.0%) and mean monthly dose (38,687 units) were lowest. Dialysis Clinic Inc, Fresenius, and Renal Care Group had the highest percentage of recommended dose adjustments (mean, 70% of units); hospital-based units had the lowest (59%). By adjusted odds ratio, adjustments were 20% more likely for Dialysis Clinic Inc, Fresenius, and Renal Care Group compared with DaVita, National Nephrology Associates, hospital-based units, and independents (17% to 28% less likely).
rHuEPO dose reduction practices are dependent on specific dialysis providers and whether units are hospital based or independent.
American Journal of Kidney Diseases 01/2007; 49(1):135-42. · 5.29 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: National payment policies target a hemoglobin range of 11 to 12.5 g/dl for patients with ESRD. However, clinical complications and provider practices may contribute to wide fluctuations over time. This study evaluated the frequency with which patients maintain stable hemoglobin levels below, within, and above the Centers for Medicare & Medicaid Services target range and assessed patterns of hemoglobin level change that resulted in large fluctuations across the target range during a 6-mo period. All hemodialysis patients who survived the first 6 mo of 2003, had Medicare as primary payer, and had Medicare outpatient erythropoietin claims in each of the first 6 mo of 2003 (n = 152,846) were studied. Six patient groups were defined on the basis of patterns of hemoglobin level fluctuation: Consistently low (<11 g/dl), consistently target range (11 to 12.5 g/dl), consistently high (> or =12.5 g/dl), low-amplitude fluctuation with low hemoglobin levels, low-amplitude fluctuation with high hemoglobin levels, and high-amplitude fluctuation. Only 10.3% of patients maintained stable hemoglobin levels during the 6 mo and only 6.5% in the target range. The consistently low group had the highest percentage of hospitalizations and the highest number of comorbid conditions. High-amplitude fluctuation was the most common pattern (39.5%), with hemoglobin levels falling below and rising above the target range during the 6-mo period. Hemoglobin levels in almost 90% of patients are in some degree of flux at any point in time, and the fluctuation is highly associated with clinical complications and provider practices.
Clinical Journal of the American Society of Nephrology 11/2006; 1(6):1205-10. · 5.07 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: The size of the prevalent ESRD population in the United States increased dramatically during the 1990s, from 196,000 in 1991 to 382,000 in 2000. Incidence also increased considerably during the same period, from 53,000 to 93,000 per year. If previous trends in ESRD incidence and prevalence continue, then current levels of health care resources that are devoted to the care of these patients will eventually be unable to meet the demand. This study discusses a Markov model developed to predict ESRD incidence, prevalence, and mortality to the year 2015 and incorporating expected changes in age/race distributions, diabetes prevalence, ESRD incidence, and probability of death. The model predicted that by 2015 there will be 136,166 incident ESRD patients per year (lower/upper limits 110,989 to 164,550), 712,290 prevalent patients (595,046 to 842,761), and 107,760 ESRD deaths annually (96,068 to 118,220). Incidence and prevalence counts are expected to increase by 44 and 85%, respectively, from 2000 to 2015 and incidence and prevalence rates per million population by 32 and 70%, respectively. The financial and human resources that will be needed to care for these patients in 2015 will be considerably greater than in 2005.
Journal of the American Society of Nephrology 01/2006; 16(12):3736-41. · 8.99 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: The impact of dialyzer reuse on the mortality of hemodialysis patients is debated. This study assesses reuse-associated mortality across US dialysis provider systems (for-profit, not-for-profit; hospital-based, and freestanding units) in incident patients.
Incident Medicare hemodialysis patients who initiated dialysis therapy from January 1, 2000, to December 31, 2001, were included and followed up to December 31, 2002. A 3-month entry period was used to determine comorbidity and disease severity. Applying various analytic approaches, mortality rates for patients treated with reused (or reprocessed) or single-use dialyzers were compared. Because of differences among dialysis units, facility clustering was addressed.
Of 75,831 patients, 61,391 patients (81.0%) were classified as on reuse, and 14,440 patients (19.0%), as on single use, as of the start of follow-up. The overall mortality rate was 25.0/100 patient-years. No difference in mortality risk was found between patients treated with reuse compared with single use in an intent-to-treat approach (hazard ratio, 0.98; 95% confidence interval, 0.94 to 1.02; P = 0.266) after adjusting for chain affiliation, for-profit status, year of dialysis inception, age, sex, race, renal diagnosis, comorbidity, and hospitalization days. Findings were similar in an as-treated approach (hazard ratio, 0.97; 95% confidence interval, 0.93 to 1.01; P = 0.136). No survival advantage associated with single use was found for subgroups.
No overall survival advantage or disadvantage is associated with dialyzer reuse compared with single use in incident hemodialysis patients in the United States; however, continued monitoring is advised.
American Journal of Kidney Diseases 11/2005; 46(4):661-8. · 5.29 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: The cost of care for end-stage renal disease (ESRD) is known to be high. The factors responsible for higher ESRD cost develop during chronic kidney disease (CKD), where the data on distribution of cost are limited.
This retrospective cohort study of 1995 through 1998 incident dialysis patients was performed to study the distribution of costs during the 24 months prior to initiation of dialysis. Patient data were obtained from the Centers for Medicare and Medicaid Services (CMS). Patients who were Medicare eligible for at least 2 years prior to initiation of dialysis were included in the study. Financial data were obtained from Medicare Part A and Part B claims and inflationary adjustments were made. The study period was divided into four segments based on overall distribution of cost.
The mean age was 75 years, 51% were males, 73% were white, and 22% were black. Overall, patient comorbidity increased significantly during the study years. Cost showed a sharp increase in the last 6 months prior to initiation of dialysis. Hospitalization was the major component of cost throughout study period. Patients who initiated hemodialysis incurred a higher cost compared to patients who initiated other modes of kidney replacement therapy. Patients with diabetes or cardiovascular disease incurred higher cost compared to those who had no diabetes or cardiovascular disease, respectively.
These data showed that hospitalization was the major component of the sharp increase in cost around the initiation of dialysis. Increased comorbidity was associated with higher cost. A focus on timely management of CKD may prevent future morbidity and costs.
Kidney International 08/2004; 66(1):313-21. · 8.52 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: The reuse of haemodialysers has been practiced in the United States for >20 years. We investigated mortality and hospitalization risk according to various reuse practices, testing the hypothesis that outcomes are improved in patients treated with dialysers cleaned with bleach and sterilized with formaldehyde.
We studied 1998 and 1999 incident Medicare haemodialysis patients, with follow-up through December 31, 2000 (49 273 patients). Clinical conditions and dialysis therapy were characterized from Medicare claims data. Included were patients who could be linked to a dialysis provider. Demographic characteristics were obtained from the Centers for Medicare and Medicaid Services (CMS) Medical Evidence Report. Mortality information was obtained from the CMS ESRD Death Notification; hospitalization information, from Medicare in-patient claims files. Data on reuse practices were obtained from the annual survey of haemodialysis units conducted by the Centers for Disease Control and Prevention.
Cox regression analyses found no significant differences in mortality or first-hospitalization risk for patients in dialysis units not using bleach as a cleaning agent. Outcomes for patients treated in units using glutaraldehyde did not vary according to use of bleach. In the analysis of first-hospitalization risk, there was no difference according to various germicide/bleach combinations. Overall, there was no significant difference in relative risk of death or in hospitalization risk among the reuse groups (including the no-reuse group).
For the 1998-1999 period, reuse practices were not associated with a survival advantage or disadvantage. Our findings may reflect the National Kidney Foundation's 1997 introduction of clinical practice guidelines, the intent of which was to bring about increased consistency of care within the dialysis community in the United States.